Bio-Techne Corp at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 04:35PM GMT
Daniel Louis Leonard - Crédit Suisse AG - Research Division - Research Analyst

All right. Greenlight means [re-life]. Our next session is Bio-Techne. We're lucky to have with us CEO of Bio-Techne, Chuck Kummeth. I'm Dan Leonard, I'm the life science tools analyst at Credit Suisse. Welcome, Chuck.

Charles R. Kummeth - Bio-Techne Corporation - CEO, President & Director

Glad to be here, Dan.

Questions and Answers:

Daniel Louis Leonard - Crédit Suisse AG - Research Division - Research Analyst

Thanks for coming. You just reported your quarter a week ago. So I thought a good way to start-off the fireside chat would be to highlight key takeaways from your September quarter results.

Charles R. Kummeth - Bio-Techne Corporation - CEO, President & Director

Sure. Well, the first thing is here it was, missed top line, I wouldn't say bottom line, but first missed ten or 11 quarters or so. But we kind of talked about that
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot